Drilldown: Medicines

Chlorhexidine gluconate (CHG) (1) · Flecainide (1) · Metoprolol (1) · Moxifloxacin (1)

Avelox (oral/IV brand discontinued US); Vigamox, Moxeza (ophthalmic) (1) · Hibiclens, Hibistat, Peridex (dental rinse), ChloraPrep (1) · Lopressor (tartrate), Toprol XL (succinate) (1) · Tambocor (US brand discontinued) (1)

Beta Blocker (1) · Cardioselective (β1) (1) · [[:Category:Antiarrhythmics|Antiarrhythmic (Vaughan-Williams class IC)]] (1) · [[:Category:Antibacterials|Antibacterial]] (1) · [[:Category:Antiseptics|Antiseptic]] (1) · [[:Category:Bisbiguanides|Bisbiguanide]] (1) · [[:Category:Fluoroquinolones|Fluoroquinolone antibiotic]] (1)

None (1) · Cardioselective β1-adrenergic antagonist. Selectivity is dose-dependent and partially lost at higher doses. (1) · '"`UNIQ--vote-00000D7A-QINU`"' Substantial QT-interval prolongation — the most QT-prolonging fluoroquinolone — limits use in patients on other QT-prolonging agents or with electrolyte abnormalities'"`UNIQ--ref-00000D7B-QINU`"'. (1) · '"`UNIQ--vote-0000113A-QINU`"' Concomitant β-blocker or CCB is required when used for AF to prevent 1:1 atrial flutter conduction (flecainide can slow atrial rate to a level where AV conduction allows dangerous ventricular rates). CYP2D6 substrate'"`UNIQ--ref-0000113B-QINU`"'. (1)

'"`UNIQ--vote-000004F5-QINU`"', '"`UNIQ--vote-000004F6-QINU`"', '"`UNIQ--vote-000004F7-QINU`"', '"`UNIQ--vote-000004F8-QINU`"', '"`UNIQ--vote-000004F9-QINU`"' (1) · '"`UNIQ--vote-00000D7C-QINU`"', '"`UNIQ--vote-00000D7D-QINU`"', '"`UNIQ--vote-00000D7E-QINU`"', '"`UNIQ--vote-00000D7F-QINU`"', '"`UNIQ--vote-00000D80-QINU`"', '"`UNIQ--vote-00000D81-QINU`"' (1) · '"`UNIQ--vote-0000113C-QINU`"', '"`UNIQ--vote-0000113D-QINU`"', '"`UNIQ--vote-0000113E-QINU`"' (1) · '"`UNIQ--vote-00001393-QINU`"', '"`UNIQ--vote-00001394-QINU`"', '"`UNIQ--vote-00001395-QINU`"', '"`UNIQ--vote-00001396-QINU`"', '"`UNIQ--vote-00001397-QINU`"' (1)

25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF (1) · 400 mg PO/IV once daily (1) · 50 mg PO BID; titrate to 100-200 mg BID; pill-in-pocket 200-300 mg PO single dose for AF conversion (1) · Surgical scrub 4% CHG; preop skin prep 2% CHG/70% isopropyl alcohol (ChloraPrep); ICU bathing 2% CHG daily; oral rinse 0.12% 15 mL twice daily for 30 seconds (1)

2%, 4% wash; 2% CHG/70% IPA applicators (ChloraPrep); 0.12%, 0.2% oral rinse; impregnated catheter dressings (1) · 400 mg tablets; 400 mg/250 mL IV; 0.5% ophthalmic solution (1) · 50, 100, 150 mg tablets (1) · Tartrate: 25, 50, 100 mg tabs; 1 mg/mL IV. Succinate ER: 25, 50, 100, 200 mg. (1)

None · Indication-specific · 40 mg/d · 10 mg/d · 20 mg/d · 80 mg/d · 10 mg/d (adults) · 100 mg/d · 4 g/d · 400 mg/d · 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison · 5 mg/d · 50 mg/d · 600 mg/d · No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals · No fixed maximum; titrated to TSH target · TID per eye · Titrated to glucose; no fixed ceiling · Titrated to glucose; no fixed maximum · '''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60

Other values:

Search

IV (2) · Oral (3) · oral rinse (do not swallow) (1) · Topical (1) · topical ophthalmic (1)

1–2 h (PO); immediate (IV) (1) · AF conversion within hours of single PO dose (1) · Hours (1) · Minutes (1)

12 hours (1) · 24 hours (1) · 6–12 h (tartrate); 24 h (succinate) (1) · Persistent activity 6+ hours (residual binding to skin and oral surfaces) (1)

3–7 h (1) · Not meaningfully described (negligible systemic absorption from intact skin or oral mucosa)'"`UNIQ--ref-00001398-QINU`"' (1) · ~12 hours'"`UNIQ--ref-00000D82-QINU`"' (1) · ~14 hours (adults); longer in elderly and renal impairment'"`UNIQ--ref-0000113F-QINU`"' (1)

Topical/oral local action with minimal systemic absorption'"`UNIQ--ref-00001399-QINU`"' (1) · ~50% (1) · ~90% (oral)'"`UNIQ--ref-00001140-QINU`"' (1) · ~90% (oral; not affected by food but reduced by divalent cations)'"`UNIQ--ref-00000D83-QINU`"' (1)

'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Category C (1) · Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Use in fetal SVT (transplacental antiarrhythmic therapy) is established; otherwise weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

OTC (lower-concentration washes) and [[USLegal:Prescription only|Rx-only]] (Peridex oral rinse, ChloraPrep) in US (1) · Rx-only in US (1) · [[USLegal:Prescription only|Rx-only]] in US. '''Contraindicated in structural heart disease''' — CAST trial (1989) showed increased mortality from class IC agents in patients with prior MI; modern use is limited to structurally normal hearts'"`UNIQ--ref-00001141-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin/levofloxacin'"`UNIQ--ref-00000D84-QINU`"' (1)